Stoke Therapeutics Inc Forecast, price target & analysts
Stoke Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Stoke Therapeutics Inc Classifications & Recommendation:
Stoke Therapeutics Inc Price Target
| Target Price | $30.60 |
| Price | $25.11 |
| Potential |
21.86%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Stoke Therapeutics Inc 2026 .
The average Stoke Therapeutics Inc target price is $30.60.
This is
21.86%
register free of charge
$40.95
63.08%
register free of charge
$15.15
39.67%
register free of charge
|
|
| A rating was issued by 17 analysts: 15 Analysts recommend Stoke Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Stoke Therapeutics Inc stock has an average upside potential 2026 of
21.86%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 36.56 | 188.82 |
| 316.40% | 416.47% | |
| EBITDA Margin | -271.33% | 6.97% |
| 78.79% | 102.57% | |
| Net Margin | -243.38% | 8.59% |
| 79.59% | 103.53% |
13 Analysts have issued a sales forecast Stoke Therapeutics Inc 2025 . The average Stoke Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Stoke Therapeutics Inc EBITDA forecast 2025. The average Stoke Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Stoke Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Stoke Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.65 | 0.30 |
| 30.67% | 118.18% | |
| P/E | 84.74 | |
| EV/Sales | 6.28 |
13 Analysts have issued a Stoke Therapeutics Inc forecast for earnings per share. The average Stoke Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Stoke Therapeutics Inc...
Current Stoke Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Oct 13 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Oct 13 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Oct 10 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 13 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
